ACHILLION PHARMACEUTICALS IN's ticker is ACHN and the CUSIP is 00448Q201. A total of 162 filers reported holding ACHILLION PHARMACEUTICALS IN in Q3 2014. The put-call ratio across all filers is 0.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $25,517,000 | +84.0% | 4,231,600 | +9.8% | 0.02% | +66.7% |
| Q3 2019 | $13,869,000 | +72.1% | 3,852,600 | +28.1% | 0.01% | +71.4% |
| Q2 2019 | $8,059,000 | +19.5% | 3,007,000 | +31.9% | 0.01% | +16.7% |
| Q1 2019 | $6,746,000 | +355.2% | 2,279,000 | +144.6% | 0.01% | +200.0% |
| Q4 2018 | $1,482,000 | +227.9% | 931,800 | +659.4% | 0.00% | – |
| Q3 2018 | $452,000 | -91.5% | 122,700 | -92.4% | 0.00% | -100.0% |
| Q2 2018 | $5,324,000 | +63.8% | 1,608,819 | +83.7% | 0.00% | -25.0% |
| Q1 2018 | $3,250,000 | -48.3% | 875,899 | -59.9% | 0.00% | -42.9% |
| Q4 2017 | $6,286,000 | +46.8% | 2,182,467 | +128.8% | 0.01% | +40.0% |
| Q3 2017 | $4,283,000 | +45.5% | 953,975 | +48.8% | 0.01% | +25.0% |
| Q2 2017 | $2,944,000 | -14.7% | 641,300 | -21.8% | 0.00% | -20.0% |
| Q1 2017 | $3,452,000 | -11.6% | 819,900 | -13.3% | 0.01% | -16.7% |
| Q4 2016 | $3,904,000 | -12.8% | 945,189 | +71.0% | 0.01% | -25.0% |
| Q3 2016 | $4,476,000 | +272.4% | 552,600 | +396.1% | 0.01% | +166.7% |
| Q4 2015 | $1,202,000 | -86.6% | 111,400 | -87.6% | 0.00% | -88.0% |
| Q3 2014 | $8,955,000 | – | 897,300 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 6,700,000 | $66,866,000 | 7.90% |
| RA Capital Management | 3,000,000 | $29,940,000 | 3.54% |
| Camber Capital Management LP | 3,250,000 | $32,435,000 | 3.05% |
| DOHENY ASSET MANAGEMENT /CA | 542,325 | $5,412,000 | 2.71% |
| QVT Financial LP | 2,504,677 | $24,997,000 | 1.29% |
| Atika Capital Management LLC | 123,700 | $1,235,000 | 0.95% |
| Rhenman & Partners Asset Management AB | 200,000 | $1,996,000 | 0.58% |
| Bain Capital Public Equity Management, LLC | 2,246,632 | $22,421,000 | 0.58% |
| BB BIOTECH AG | 1,279,340 | $12,768,000 | 0.52% |
| EAM Investors, LLC | 222,842 | $2,224,000 | 0.45% |